BR112022015579A2 - Composições para tratamento de doenças oculares - Google Patents
Composições para tratamento de doenças ocularesInfo
- Publication number
- BR112022015579A2 BR112022015579A2 BR112022015579A BR112022015579A BR112022015579A2 BR 112022015579 A2 BR112022015579 A2 BR 112022015579A2 BR 112022015579 A BR112022015579 A BR 112022015579A BR 112022015579 A BR112022015579 A BR 112022015579A BR 112022015579 A2 BR112022015579 A2 BR 112022015579A2
- Authority
- BR
- Brazil
- Prior art keywords
- eye diseases
- edonentan
- agent
- compositions
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971002P | 2020-02-06 | 2020-02-06 | |
| US202063010212P | 2020-04-15 | 2020-04-15 | |
| PCT/US2021/016414 WO2021158663A1 (en) | 2020-02-06 | 2021-02-03 | Compositions for treatment of ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015579A2 true BR112022015579A2 (pt) | 2022-10-11 |
Family
ID=77200537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015579A BR112022015579A2 (pt) | 2020-02-06 | 2021-02-03 | Composições para tratamento de doenças oculares |
Country Status (11)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7664239B2 (ja) * | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| BR112023022705A2 (pt) | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
| CN117295520A (zh) * | 2021-04-30 | 2023-12-26 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
| WO2025137005A1 (en) * | 2023-12-20 | 2025-06-26 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
| AU2024405327A1 (en) * | 2023-12-20 | 2026-07-02 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4282793A (en) | 1992-04-10 | 1993-11-18 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| CZ20032350A3 (en) | 2001-02-02 | 2004-03-17 | Merck Patent Gmbh | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS |
| US20030176356A1 (en) * | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| PL2424530T3 (pl) | 2009-04-30 | 2016-07-29 | Univ Midwestern | Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej |
| US20110082151A1 (en) | 2009-06-12 | 2011-04-07 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| AR080888A1 (es) | 2010-04-12 | 2012-05-16 | R Tech Ueno Ltd | Uso de un derivado de acido graso para producir una composicion oftalmica |
| ES2813383T3 (es) | 2013-12-19 | 2021-03-23 | Tassos Georgiou | Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso |
| RU2016133980A (ru) * | 2014-01-23 | 2018-03-01 | Экебиа Терапьютикс, Инк. | Композиции и способы для лечения заболеваний глаз |
| ES2584534B1 (es) | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| JP2018522942A (ja) | 2015-05-29 | 2018-08-16 | エッジ セラピューティクス インコーポレイテッド | 視力障害を低減するための組成物及び方法 |
| JP6745594B2 (ja) * | 2015-11-26 | 2020-08-26 | 持田製薬株式会社 | ピラゾール誘導体の塩の結晶 |
| WO2017217967A1 (en) | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
| WO2018185516A1 (en) * | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| US10905770B2 (en) | 2017-07-17 | 2021-02-02 | Macregen, Inc. | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases |
| KR102771305B1 (ko) * | 2017-09-15 | 2025-02-24 | 모찌다 세이야쿠 가부시끼가이샤 | 테트라히드로나프틸우레아 유도체의 결정 |
| WO2019210194A1 (en) | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| JP7664239B2 (ja) | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
-
2021
- 2021-02-03 CA CA3168810A patent/CA3168810A1/en active Pending
- 2021-02-03 EP EP21751181.5A patent/EP4100406A4/en active Pending
- 2021-02-03 CN CN202180013043.1A patent/CN115103842A/zh active Pending
- 2021-02-03 IL IL294873A patent/IL294873A/en unknown
- 2021-02-03 MX MX2022009677A patent/MX2022009677A/es unknown
- 2021-02-03 BR BR112022015579A patent/BR112022015579A2/pt unknown
- 2021-02-03 WO PCT/US2021/016414 patent/WO2021158663A1/en not_active Ceased
- 2021-02-03 AU AU2021217358A patent/AU2021217358A1/en active Pending
- 2021-02-03 JP JP2022547697A patent/JP2023512763A/ja active Pending
- 2021-02-03 KR KR1020227030697A patent/KR20220143685A/ko active Pending
-
2022
- 2022-08-02 US US17/879,627 patent/US11873279B2/en active Active
-
2023
- 2023-12-04 US US18/528,378 patent/US20240109876A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093285A patent/JP2025120268A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3168810A1 (en) | 2021-08-12 |
| MX2022009677A (es) | 2022-09-09 |
| AU2021217358A1 (en) | 2022-09-08 |
| US20230120974A1 (en) | 2023-04-20 |
| US11873279B2 (en) | 2024-01-16 |
| CN115103842A (zh) | 2022-09-23 |
| IL294873A (en) | 2022-09-01 |
| EP4100406A1 (en) | 2022-12-14 |
| KR20220143685A (ko) | 2022-10-25 |
| JP2023512763A (ja) | 2023-03-29 |
| EP4100406A4 (en) | 2023-07-05 |
| JP2025120268A (ja) | 2025-08-15 |
| WO2021158663A1 (en) | 2021-08-12 |
| US20240109876A1 (en) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grob et al. | Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions | |
| MX2022009677A (es) | Composiciones para el tratamiento de enfermedades oculares. | |
| MX2022005063A (es) | Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina. | |
| BR112015001158A2 (pt) | formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia | |
| MX2020009132A (es) | Composiciones farmaceuticas que comprenden nebivolol. | |
| Vajpayee et al. | Intrastromal fluid drainage with air tamponade: anterior segment optical coherence tomography guided technique for the management of acute corneal hydrops | |
| Guo et al. | Scleral cross-linking in form-deprivation myopic guinea pig eyes leads to glaucomatous changes | |
| BR112021023251A2 (pt) | Tratamento da doença ocular | |
| Nordmann et al. | Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with β adrenergic antagonists | |
| MX2020011535A (es) | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. | |
| BR112022014456A2 (pt) | Tafoxiparina para o tratamento da pré-eclâmpsia | |
| Karatas et al. | Intravitreal ranibizumab versus intravitreal ranibizumab combined with posterior subtenon triamcinolone acetonide in diabetic macular edema | |
| Arenas-Archila et al. | Intra-lesional injection of betamethasone for the treatment of symptomatic pinguecula | |
| Belkin et al. | Direct trans-scleral selective laser trabeculoplasty (SLT) without a gonioscopy lens | |
| Kazanova et al. | Analysis of glaucoma process progression rates depending on various treatment non-compliance scenarios | |
| Santos-Bueso et al. | Scheie's line as a first sign of pigment dispersion syndrome | |
| Mortensen | Corneal ectasia after PRK | |
| AR056092A1 (es) | Tratamiento de inflamaciones y anomalias vasculares oftalmologicas | |
| Erichev et al. | Selective sympathomimetics in monoand combination glaucoma therapy | |
| Filatova et al. | The effectiveness of additional medical management of patients in the early stages after reconstructive interventions on the auxiliary apparatus of the eye: assessment of changes in the tissues of the ocular surface and eyelids | |
| Ali et al. | Correlation between serum 25-hydroxyvitamin D levels and VEP and OCT in patients with primary open-angle glaucoma | |
| Ho et al. | Long-term natural course of lattice degeneration of the retina in high myopic eyes-A ten-year long term study. | |
| Lovpache | Using a fixed combination Dorsopt Plus in patients with various clinical forms of primary open angle glaucoma: the results of an 18-month follow-up | |
| Iomdina | Drug therapy of magnesium deficiency in patients with primary open angle glaucoma (POAG) | |
| Alekseev et al. | Comparison of the effectiveness and safety of monotherapy with 0.03% bimatoprost (Bimatan®) and 0.005% latanoprost (Xalatan®) in patients with primary open-angle glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 413/12 , C07D 413/14 , C07D 413/00 Ipc: C07D 413/12 (2006.01), C07D 413/14 (2006.01), C07D |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |